Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Crinetics Pharmaceuticals Inc (NQ: CRNX ) 54.02 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Crinetics Pharmaceuticals Inc < Previous 1 2 3 4 5 6 Next > Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why March 19, 2024 Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy & safety, with plans for FDA submission in 2024. Via Benzinga Exposures Product Safety Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 19, 2024 Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. Via Benzinga Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Leading the Way in Tuesday Trading Based on Percentage Gain March 19, 2024 Via Investor Brand Network The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 Experts February 29, 2024 Via Benzinga Crinetics Pharmaceuticals: Q4 Earnings Insights February 28, 2024 Via Benzinga Crinetics Pharmaceuticals Earnings Preview February 27, 2024 Via Benzinga Analyst Scoreboard: 4 Ratings For Crinetics Pharmaceuticals December 19, 2023 Via Benzinga National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday March 19, 2024 U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win March 19, 2024 Biotech stock Crinetics Pharmaceuticals rocketed early Tuesday after solid trial results for its oral growth hormone treatment. Via Investor's Business Daily Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients March 19, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome March 12, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire 8 Analysts Have This to Say About Crinetics Pharmaceuticals November 20, 2023 Via Benzinga 11 Analysts Have This to Say About Crinetics Pharmaceuticals October 24, 2023 Via Benzinga Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 11, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday March 01, 2024 U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Via Benzinga Topics Stocks Exposures US Equities Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update February 28, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement February 28, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 February 14, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 12, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire 10 Health Care Stocks With Whale Alerts In Today's Session January 23, 2024 Via Benzinga Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session December 28, 2023 Via Benzinga Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study December 19, 2023 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound... Via Benzinga Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome December 18, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 11, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences November 20, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 10, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 07, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment October 11, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END Via FinancialNewsMedia < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.